

OPERATIONAL UPDATES
OCTOBER 2023

HIGHLIGHTS

- Singapore Health regulatory approval for the commercial use of clinical **Onco-PDO™**.
- First Licensing deal signed in Thailand.
- Invivocue's Humanized Mice business (HiMice) continues third year profitability.
- Stabilization of Revenue growth through new key accounts in Europe and USA.
- New Business and Services using DNA Methylation for the early and advanced detection and intervention of chronic diseases.

9 November 2023: Personalized Oncology and diagnostic life sciences company **Invitrocue Limited** ('Invitrocue', 'the Company' or 'the Group') is pleased to provide this Management and Operational update.

SINGAPORE MINISTRY OF HEALTH APPROVAL FOR ONCO-PDO™

The Singapore Ministry of Health (MOH) has granted Invitrocue Singapore its HCSA License for the commercial sales and use of its patented and proprietary personalized cancer drug screening services. In addition to Singapore, the company has also received the respective local accreditation and approval from Germany with CE Mark and Hong Kong since 2019 and 2021 respectively.

Onco-PDO uses a sample of cancer patient's biopsy to provide an individualized assessment of the efficacy of various cancer drugs on patient's cancer treatment.

ONCO-PDO™ CANCER ORGANOIDS FOR PHARMACOLOGY

Leveraging our growing database and cryogenic inventories of Onco-PDO™ Cancer Organoids, Invitrocue Singapore have made significant progress in securing key contracts with leading global pharmaceutical companies in the use of Onco-PDO™ in pre-clinical pharmacology services. The company expects this area of service to continue to grow given the growth in novel drug development initiatives globally since the lifting of the Covid19 pandemic restrictions.

HiMice™

Invitrocue's humanized mice business now extends to the supply of both mice and pharmacological services using our in-house produced Humanized Immune Mice, Humanized Liver Mice and a dual humanized model that includes both a humanized immune and humanized liver model in the same mice. This business continues to be a key revenue contributor.

In addition, several new Master Service Agreements were signed during this period with key global pharmaceutical and biotechnology companies to provide both its Onco-PDO™ based pharmacology services and HiMice™ based in-vivo testing for drug development and validation. These new



agreements have filled up our laboratory capacities to March 2024, with expectation that the several contract discussions currently in the pipeline to be signed which will fill up our capacity for the remaining months of 2024 financial year.

Additionally, the company is now able to secure key academic accounts from research institutions such as University of Heidelberg, to manage and fulfill several of its inhouse research initiatives. UOH currently operates with an annual research budget of approximately EUR\$100 million. Invitrocue and Invivocue have already received several such contracts from University of Heidelberg

EPIGENETICS – MYTRUHEALTH™ & MYTRUAGE™ DNA METHYLATION TESTS

Invitrocue Singapore has also launched its in house MyTruHealth™ DNA Methylation based Tests to focus and offer an advanced screening of chronic diseases including the quantification of Biological Age, Immune Age and Pace of Aging. The test is currently being sold exclusively through qualified medical clinics as part of its health screening and interventions for longevity and against selected chronic diseases.

Compared to traditional DNA Tests which can only report on the gene patterns, MyTruHealth™ looks at the “activation” or gene expression, providing an accurate and affordable way to map specific genomic activities of an individual. Given that most Methylation attachments are reversible through a complex process of Active and Passive Demethylation, our test not only maps such gene expression that triggers chronic diseases but offers a means to quantify the effects of clinical interventions against specific chronic diseases for an individual.

This test is available commercially in Singapore, Germany Hong Kong, Malaysia, and Thailand. Interests are also being represented from several other markets.

END

For further information, please contact:

Martin D. Bach

VP Operations

M: +65 6460 0497

E: martind.bach@invitrocue.com

www.invitrocue.com

About Invitrocue (IVQ)

Invitrocue Limited (IVQ) is an innovative life sciences company commercializing products and services in Oncology and Pharmacology, based on ground-breaking 3D models and Humanized mice platform. Headquartered in Singapore and with operations in Australia, Hong Kong, Thailand, and Germany, Invitrocue’s in-vitro Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalized clinical decisions.



In addition, InvitroCue's HiMice novel technology allows for the in-vivo testing of drugs and vaccines using a stable and fully human immune response.

To learn more, please visit: www.invitrocue.com